Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF internal deletions and resistance to BRAF / MEK inhibitor therapy

24 Nov 2017

Abstract excerpt

Summary BRAF and MEK inhibitors have improved clinical outcomes in advanced, BRAFV600‐mutated melanomas. Acquired resistance occurs in most patients, with numerous and diverse drivers. We obtained pretreatment and progression biopsies from a patient who progressed on dabrafenib and trametinib. In addition to a preserved BRAFV600E mutation, an internal deletion (rearrangement) of BRAF was observed in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29171936
DOI: 10.1111/pcmr.12674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF internal deletions and resistance to BRAF / MEK inhibitor therapyPMID 29171936Read ↗

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Semantic proximity Read ↗

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.Semantic proximity Read ↗

Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanomaSemantic proximity Read ↗

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.Semantic proximity Read ↗

MEK1 mutations confer resistance to MEK and B-RAF inhibitionSemantic proximity Read ↗

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.Semantic proximity Read ↗

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E MutationSemantic proximity Read ↗

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicingSemantic proximity Read ↗

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.Semantic proximity Read ↗

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.Semantic proximity Read ↗

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.Semantic proximity Read ↗

An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.